Novel Diagnostics for Ocular Structure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00286637

Recruitment Status : Recruiting

First Posted : February 3, 2006

Last Update Posted : August 24, 2020

See Contacts and Locations

Sponsor:

Collaborator:

National Eye Institute (NEI)

Information provided by (Responsible Party):

NYU Langone Health

Study Description

Brief Summary:

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Condition or disease
Glaucoma Macular Disease

Show detailed description

Detailed Description:

Objective:

The purpose of this research is to evaluate a new technology, optical coherence tomography (OCT), to image diseases of the eye and to compare the measurements obtained using OCT with those of other imaging and visual field devices. OCT may be useful for the early diagnosis and monitoring of a variety of eye diseases such as age-related macular degeneration (ARMD), glaucoma, diabetic retinopathy, macular edema, and other pathologies.

Specific Aims:

There are three sub-studies: cross-sectional, longitudinal and reproducibility. The cross-sectional and longitudinal arms study the effectiveness of the OCT technology in terms of detecting and monitoring eye diseases. The reproducibility study is designed to test the measurement likeness of the OCT.

Background:

This is a continuation of an ongoing study from the New England Eye Center (NEEC), Tufts Medical Center, Boston, MA. This study started when our research group was located at NEEC and in collaboration with the Massachusetts Institute of Technology (MIT) where we conducted the first clinical studies with OCT. The first investigation using OCT was published in Science in 1991 and showed in vitro imaging of the human retina and atherosclerotic plaque. We developed an OCT prototype system for performing preliminary ophthalmic clinical studies and in 1993, began clinical OCT imaging studies.

The prototype ophthalmic OCT instrument acquired OCT images of the retina with an axial resolution of 10µm within an acquisition time of 2.5 sec. The OCT imaging system was integrated with a slit-lamp biomicroscope for in vivo tomography of the anterior and posterior eye. The beam is directed into the eye using computer controlled galvonometric scanners, which can scan arbitrary transverse patterns. The beam focus is coincident with the slit-lamp image plane to permit simultaneous scanning and visualization of the eye through the slit-lamp or via a CCD camera. For tomography of the anterior eye, the microscope is focused directly on the structure, while for retinal imaging, a lens relay images of the retina onto the slit-lamp image plane. A computer provides real-time display of the tomogram, image processing, and data management.

OCT technology was patented and subsequently transferred to industry (Zeiss Humphrey Systems, CA). Our prototype ophthalmic OCT system was developed into a clinical instrument and was introduced into the ophthalmic market in 1996. The commercial OCT technology has an axial resolution of 10 µm and can acquire a 100 transverse pixel retinal tomogram in 1 second. A third generation ophthalmic OCT imaging device, OCT3, was introduced three years ago. OCT imaging is now used as a standard diagnostic procedure as part of an ophthalmic examination for many retina and glaucoma patients at the University of Pittsburgh Medical Center (UPMC) Eye Center and New England Eye Center (NEEC). OCT imaging is in use in major research and clinical centers internationally. The OCT has been approved by the Food and Drug Administration for use in ophthalmology.

Significance:

OCT enables tissue pathology to be imaged in situ and in real time with a resolution approaching that of conventional histopathology but without the need for excising and processing specimens. OCT provides a quantitative method of directly measuring ocular structures with high precision and could provide an objective, early diagnosis for glaucoma, age related macular degeneration (ARMD), diabetic retinopathy, macular edema, and other pathologies. Extensive studies have been performed with OCT in cross-sectional as well as longitudinal setting. In this ongoing protocol, our objective is to continue these studies using the commercial ophthalmic OCT imaging instruments to develop methods for early detection and improve longitudinal assessment for the above mentioned ocular pathologies.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	2767 participants
Observational Model:	Other
Time Perspective:	Other
Official Title:	Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure
Study Start Date :	January 1995
Estimated Primary Completion Date :	January 2024
Estimated Study Completion Date :	January 2025

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Early-onset glaucoma Hypertension

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Novel Diagnostics for Ocular Structure [ Time Frame: 5 years ]
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Recruiting subjects male or female, ages beginning at 18 with Macular dgegeneration, diabetic retinopathy, and/or glaucoma. Can also be a normal/healthy subject.

Criteria

Inclusion Criteria:

Age older than or equal to 18 years old
Macular Degeneration, Diabetic Retinopathy, and/or glaucoma patients.
Normal control subjects

Exclusion Criteria:

Media opacity (lens, vitreous, cornea)
Strabismus, nystagmus, or a condition that would prevent fixation.
Inability to understand informed consent

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286637

Contacts

Layout table for location contacts

Contact: Stacy L Mach	646-501-9883	Stacy.Mach@nyumc.org

Locations

Layout table for location information

United States, New York
New York University School of Medicine	Recruiting
New York, New York, United States, 10016
Contact: Stacy L Mach 646-501-9883 Stacy.Mach@nyumc.org
Principal Investigator: Joel S Schuman, MD
Sub-Investigator: Gadi Wollstein, MD
Sub-Investigator: Hiroshi Ishikawa, MD
Sub-Investigator: Ian Conner, MD, PhD

Sponsors and Collaborators

NYU Langone Health

National Eye Institute (NEI)

Investigators

Layout table for investigator information

Study Chair:	Joel S Schumann, MD	NYU Langone Health

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mumcuoglu T, Townsend KA, Wollstein G, Ishikawa H, Bilonick RA, Sung KR, Kagemann L, Schuman JS; Advanced Imaging in Glaucoma Study Group. Assessing the relationship between central corneal thickness and retinal nerve fiber layer thickness in healthy subjects. Am J Ophthalmol. 2008 Oct;146(4):561-6. doi: 10.1016/j.ajo.2008.05.038. Epub 2008 Jul 26.

Gabriele ML, Ishikawa H, Wollstein G, Bilonick RA, Townsend KA, Kagemann L, Wojtkowski M, Srinivasan VJ, Fujimoto JG, Duker JS, Schuman JS. Optical coherence tomography scan circle location and mean retinal nerve fiber layer measurement variability. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2315-21. doi: 10.1167/iovs.07-0873.

Layout table for additonal information

Responsible Party:	NYU Langone Health
ClinicalTrials.gov Identifier:	NCT00286637
Other Study ID Numbers:	R01EY013178-06 ( U.S. NIH Grant/Contract ) R01EY011289-21 ( U.S. NIH Grant/Contract ) P30EY008098 ( U.S. NIH Grant/Contract ) 16-01302 ( Other Identifier: NYUMC IRB )
First Posted:	February 3, 2006 Key Record Dates
Last Update Posted:	August 24, 2020
Last Verified:	August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by NYU Langone Health:


OCT CSLO SLP Perimetry electrophysiology	glaucoma macular degeneration retinopathy diabetes macular hole

Additional relevant MeSH terms:

Layout table for MeSH terms

Glaucoma Ocular Hypertension Eye Diseases

To Top